SEO URLwww.firestrike.ai/deals/hengrui-pharma-bristol-myers-squibb-acquisition-2026
acquisitionAnnounced · Jun 1, 2026PharmaceuticalsSource · CredibleArticle · Factual
Bristol-Myers Squibb acquires Hengrui Pharma
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
Deal value
$15B
Target
Hengrui Pharma
Shanghai, Shanghai
Acquirer
Bristol-Myers Squibb
Full Acquisition
Status
Announced
Bristol-Myers Squibb agreed to acquire Hengrui Pharma. Reported deal value: $15B. Status: Announced. Sector: Pharmaceuticals. Target headquarters context: Shanghai, Shanghai, China.
This page summarizes publicly available information about the transaction as of 2026-06-01. Figures and status may change as filings and press coverage update.
Bristol Myers Squibb CEO on $ 15B deal with China Hengrui Pharma
Deal timeline
Announced
Jun 1, 2026 · cnbc.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Pharmaceuticals with a reported deal value of $15B. Figures and status may change as sources update.
Sources: cnbc.com · Primary article · FireStrike proprietary index